P
P. N. Grozea
Researcher at University of Oklahoma Health Sciences Center
Publications - 9
Citations - 699
P. N. Grozea is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Vincristine & CHOP. The author has an hindex of 7, co-authored 9 publications receiving 696 citations.
Papers
More filters
Journal ArticleDOI
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.
Dennis O. Dixon,B Neilan,Stephen E. Jones,D A Lipschitz,Thomas P. Miller,P. N. Grozea,Henry E. Wilson +6 more
TL;DR: It is suggested that older age is associated with a worse prognosis in advanced DHL, and the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.
Journal ArticleDOI
Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
Merrill S. Kies,J. G. Mira,J. J. Crowley,T. T. Chen,R. Pazdur,P. N. Grozea,Saul E. Rivkin,Charles A. Coltman,J. H. Ward,Robert B. Livingston +9 more
TL;DR: This phase III study was designed to determine the value of chest radiation in limited-stage small-cell lung cancer patients achieving complete response after induction chemotherapy, and to test the use of wide-field v more limited-volume radiation in patients with partial responses (PRs) and patients with stable disease (SD).
Journal ArticleDOI
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.
Stephen E. Jones,P. N. Grozea,Thomas P. Miller,E J Van Slyck,Stanley P. Balcerzak,John J. Costanzi,Francis S. Morrison,Harmon J. Eyre,Carol J. Fabian,L Dabich +9 more
TL;DR: Chemoimmunotherapy with levamisole or levam isole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levam Isole may have had an adverse impact on outcome in certain subtypes of ML.
Journal ArticleDOI
Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease: A southwest oncology group study
Carl M. Mansfield,Carol J. Fabian,Stephen E. Jones,Ellis J. Van Slyck,P. N. Grozea,Francis S. Morrison,Thomas P. Miller,Candy Seibert,Komanduri M. Ayyangar +8 more
TL;DR: It is suggested that LAG of the lower abdomen provided more information than CT, and therefore should not be abandoned as a valid method for detecting nodal disease.
Journal ArticleDOI
VP‐16 + adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A southwest oncology group study
Clarence B. Vaughn,Stephanie Green,Robert M. O'Bryan,Melvin L. Reed,P. N. Grozea,William S. Fletcher,J. Benjamin Green,Barbara Metch,Noboru Oishi +8 more
TL;DR: The addition of VP-16 to adriamycin does not offer an important clinical advantage and time to progression was delayed on the combination arm, and survival in both arms was similar.